ArticleHuman vaccines & immunotherapeutics2026
Willingness to accept the Dengue vaccine among adult Malaysians - An online survey.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studying the willingness to accept a new vaccine helps better understand the consumer behavior to formulate strategies to improve its acceptance when rolled out on a large scale. An online survey using a quota sampling covering all Malaysian states and territories was conducted. A pretested and validated questionnaire covering willingness under four hypothetical scenarios of the Dengue vaccine on a Juster scale and factors related to Dengue knowledge, vaccine, and prevention was used. By multiple linear regression, we identified the factors associated with the Dengue vaccine willingness score. The respondents' mean age was 38.7 y (SD = 11.5). Mean willingness score for Dengue vaccine under development was highest if efficacy is 95% and no side effect was 7.9 (SD = 2.2), and an authorized Dengue vaccine if recommended by a physician was about 7.2 (SD = 2.3). The significant covariates positively associated with the willingness score were female sex, perceived susceptibility, knowledge about symptoms, beliefs about Dengue vaccination, and perceptions about Dengue prevention. In contrast, higher education, past Dengue infection, and vaccine-related concerns were negatively associated with willingness score. Our national survey indicates that willingness to accept the Dengue vaccine was positive. The positive association of perceptions toward disease susceptibility and severity, beliefs toward Dengue vaccination and preventive programs, with willingness, suggests a conducive ground for potential Dengue vaccine rollout. Public education be provided about the Dengue vaccine to address their concerns about the vaccine, and post-marketing surveillance be done.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.